Michael J Lenardo

List of Publications by Year
in descending order

144	30,226	66	136
papers	citations	h-index	g-index
		14655	11308

147	147	147	29583
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	A Double-Blind, Placebo-Controlled, Crossover Study of Magnesium Supplementation in Patients with XMEN Disease. Journal of Clinical Immunology, 2022, 42, 108-118.	3.8	14
2	Mucus sialylation determines intestinal host-commensal homeostasis. Cell, 2022, 185, 1172-1188.e28.	28.9	66
3	Congenital iRHOM2 deficiency causes ADAM17 dysfunction and environmentally directed immunodysregulatory disease. Nature Immunology, 2022, 23, 75-85.	14.5	3
4	GIMAP6 regulates autophagy, immune competence, and inflammation in mice and humans. Journal of Experimental Medicine, 2022, 219, .	8.5	4
5	MAGT1 messenger RNA-corrected autologous T and natural killer cells for potential cell therapy in X-linked immunodeficiency with magnesium defect, Epstein-Barr virus infection and neoplasia disease. Cytotherapy, 2021, 23, 203-210.	0.7	7
6	Homozygous <i>IL37</i> mutation associated with infantile inflammatory bowel disease. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	7.1	17
7	GIMAP5 maintains liver endothelial cell homeostasis and prevents portal hypertension. Journal of Experimental Medicine, 2021, 218, .	8.5	22
8	CRISPR-targeted<i>MAGT1</i>insertion restores XMEN patient hematopoietic stem cells and lymphocytes. Blood, 2021, 138, 2768-2780.	1.4	20
9	Two patients with chronic mucocutaneous candidiasis caused by TRAF3IP2 deficiency. Journal of Allergy and Clinical Immunology, 2021, 148, 256-261.e2.	2.9	10
10	<scp>NFâ€ÎºB</scp> Rel subunit exchange on a physiological timescale. Protein Science, 2021, 30, 1818-1832.	7.6	8
11	Broadly effective metabolic and immune recovery with C5 inhibition in CHAPLE disease. Nature Immunology, 2021, 22, 128-139.	14.5	23
12	Exome sequencing study in a clinical research setting finds general acceptance of study returning secondary genomic findings with little decisional conflict. Journal of Genetic Counseling, 2021, 30, 766-773.	1.6	4
13	A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nature Reviews Immunology, 2020, 20, 651-668.	22.7	2,160
14	An Update on XMEN Disease. Journal of Clinical Immunology, 2020, 40, 671-681.	3.8	53
15	Extended clinical and immunological phenotype and transplant outcome in CD27 and CD70 deficiency. Blood, 2020, 136, 2638-2655.	1.4	64
16	HEM1 deficiency disrupts mTORC2 and F-actin control in inherited immunodysregulatory disease. Science, 2020, 369, 202-207.	12.6	65
17	Combined immune deficiencies (CIDs). , 2020, , 207-268.		2
18	Magnesium transporter 1 (MAGT1) deficiency causes selective defects in N-linked glycosylation and expression of immune-response genes. Journal of Biological Chemistry, 2019, 294, 13638-13656.	3.4	57

#	Article	IF	Citations
19	Mg2+ regulation of kinase signaling and immune function. Journal of Experimental Medicine, 2019, 216, 1828-1842.	8.5	37
20	Development of immune checkpoint therapy for cancer. Journal of Experimental Medicine, 2019, 216, 1244-1254.	8.5	125
21	Human interleukin-2 receptor Î² mutations associated with defects in immunity and peripheral tolerance. Journal of Experimental Medicine, 2019, 216, 1311-1327.	8.5	62
22	F-BAR domain only protein 1 (FCHO1) deficiency is a novel cause of combined immune deficiency in human subjects. Journal of Allergy and Clinical Immunology, 2019, 143, 2317-2321.e12.	2.9	21
23	Introduction: Continuing insights into the healthy and diseased immune system through human genetic investigation. Immunological Reviews, 2019, 287, 5-8.	6.0	1
24	Defective glycosylation and multisystem abnormalities characterize the primary immunodeficiency XMEN disease. Journal of Clinical Investigation, 2019, 130, 507-522.	8.2	74
25	Gene Editing and mRNA-Based Therapy: Two Complementary Therapeutic Approaches for the Treatment of Patients with Xmen Disease. Blood, 2019, 134, 4637-4637.	1.4	0
26	Plasma magnesium is inversely associated with Epstein-Barr virus load in peripheral blood and Burkitt lymphoma in Uganda. Cancer Epidemiology, 2018, 52, 70-74.	1.9	17
27	RELA haploinsufficiency in CD4 lymphoproliferative disease with autoimmune cytopenias. Journal of Allergy and Clinical Immunology, 2018, 141, 1507-1510.e8.	2.9	31
28	STAT5B: A Differential Regulator of the Life and Death of CD4+ Effector Memory T Cells. Journal of Immunology, 2018, 200, 110-118.	0.8	29
29	Clinical, Immunological, and Molecular Findings in Four Cases of B Cell Expansion With NF-Îº B and T Cell Anergy Disease for the First Time From India. Frontiers in Immunology, 2018, 9, 1049.	4.8	22
30	Molecular Classification of Primary Immunodeficiencies of T Lymphocytes. Advances in Immunology, 2018, 138, 99-193.	2.2	9
31	30 Years of NF-ÎºB: A Blossoming of Relevance to Human Pathobiology. Cell, 2017, 168, 37-57.	28.9	1,437
32	Metabolically inactive insulin analogue does not prevent autoimmune diabetes in NOD mice. Diabetologia, 2017, 60, 1475-1482.	6.3	8
33	Restimulationâ€induced cell death: new medical and research perspectives. Immunological Reviews, 2017, 277, 44-60.	6.0	23
34	Combined immunodeficiency and Epstein-Barr virusâ€“induced B cell malignancy in humans with inherited CD70 deficiency. Journal of Experimental Medicine, 2017, 214, 91-106.	8.5	134
35	Effective â€œactivated PI3KÎ´ syndromeâ€â€“targeted therapy with the PI3KÎ´ inhibitor leniolisib. Blood, 2017, 130, 2307-2316.	1.4	227
36	CD55 Deficiency and Protein-Losing Enteropathy. New England Journal of Medicine, 2017, 377, 1499-1500.	27.0	12

#	ARTICLE	IF	CITATIONS
37	CD55 Deficiency, Early-Onset Protein-Losing Enteropathy, and Thrombosis. New England Journal of Medicine, 2017, 377, 52-61.	27.0	138
38	Large Deletion of MAGT1 Gene in a Patient with Classic Kaposi Sarcoma, CD4 Lymphopenia, and EBV Infection. Journal of Clinical Immunology, 2017, 37, 32-35.	3.8	38
39	Characterization of a genetically engineered mouse model of hemophilia A with complete deletion of the F8 gene. Journal of Thrombosis and Haemostasis, 2016, 14, 346-355.	3.8	12
40	Clinical Genomics â€” Molecular Pathogenesis Revealed. New England Journal of Medicine, 2016, 375, 2117-2119.	27.0	0
41	Clinical and immunologic phenotype associated with activated phosphoinositide 3-kinase Î´ syndrome 2: AÂcohort study. Journal of Allergy and Clinical Immunology, 2016, 138, 210-218.e9.	2.9	215
42	Genomics of Immune Diseases and New Therapies. Annual Review of Immunology, 2016, 34, 121-149.	21.8	47
43	Mitochondrial Protein PGAM5 Regulates Mitophagic Protection against Cell Necroptosis. PLoS ONE, 2016, 11, e0147792.	2.5	102
44	JMML and RALD (Ras-associated autoimmune leukoproliferative disorder): common genetic etiology yet clinically distinct entities. Blood, 2015, 125, 2753-2758.	1.4	94
45	Clinical utility gene card for: X-linked immunodeficiency with magnesium defect, Epsteinâ€"Barr virus infection, and neoplasia (XMEN). European Journal of Human Genetics, 2015, 23, 889-889.	2.8	5
46	Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy. Science, 2015, 349, 436-440.	12.6	580
47	Identifying genetic determinants of autoimmunity and immune dysregulation. Current Opinion in Immunology, 2015, 37, 28-33.	5.5	10
48	Bill Paul: The heart of immunology. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 14117-14118.	7.1	0
49	Genomics is rapidly advancing precision medicine for immunological disorders. Nature Immunology, 2015, 16, 1001-1004.	14.5	29
50	Novel diagnostic and therapeutic approaches for autoimmune diabetes â€” A prime time to treat insulitis as a disease. Clinical Immunology, 2015, 156, 109-118.	3.2	7
51	Heterozygous splice mutation in <i>PIK3R1</i> causes human immunodeficiency with lymphoproliferation due to dominant activation of PI3K. Journal of Experimental Medicine, 2014, 211, 2537-2547.	8.5	249
52	Combined Immune Deficiencies. , 2014, , 143-169.		3
53	Dual Proteolytic Pathways Govern Glycolysis and Immune Competence. Cell, 2014, 159, 1578-1590.	28.9	54
54	XMEN disease: a new primary immunodeficiency affecting Mg2+ regulation of immunity against Epstein-Barr virus. Blood, 2014, 123, 2148-2152.	1.4	147

#	ARTICLE	IF	CITATIONS
55	X-linked immunodeficiency with magnesium defect, Epsteinâ€“Barr virus infection, and neoplasia disease. Current Opinion in Pediatrics, 2014, 26, 713-719.	2.0	52
56	Natural history of autoimmune lymphoproliferative syndrome associated with FAS gene mutations. Blood, 2014, 123, 1989-1999.	1.4	204
57	Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110Î´ result in T cell senescence and human immunodeficiency. Nature Immunology, 2014, 15, 88-97.	14.5	575
58	Monogenic Autoimmune Lymphoproliferative Syndromes. , 2014, , 695-709.		0
59	Genetic deficiency of the mitochondrial protein PGAM5 causes a Parkinsonâ€™s-like movement disorder. Nature Communications, 2014, 5, 4930.	12.8	118
60	Immune dysregulation in human subjects with heterozygous germline mutations in <i>CTLA4</i>. Science, 2014, 345, 1623-1627.	12.6	745
61	Divalent cation signaling in immune cells. Trends in Immunology, 2014, 35, 332-344.	6.8	56
62	Molecular Basis of Cell Death Programs in Mature T Cell Homeostasis. , 2014, , 41-59.		0
63	Mg ²⁺ Regulates Cytotoxic Functions of NK and CD8 T Cells in Chronic EBV Infection Through NKG2D. Science, 2013, 341, 186-191.	12.6	269
64	A Rapid Ex Vivo Clinical Diagnostic Assay for Fas Receptor-Induced T Lymphocyte Apoptosis. Journal of Clinical Immunology, 2013, 33, 479-488.	3.8	14
65	Programmed cell death in lymphocytes and associated disorders. , 2013, , 172-180.		0
66	Congenital B cell lymphocytosis explained by novel germline <i>CARD11</i> mutations. Journal of Experimental Medicine, 2012, 209, 2247-2261.	8.5	167
67	Second messenger role for Mg2+ revealed by human T-cell immunodeficiency. Nature, 2011, 475, 471-476.	27.8	465
68	The Molecular Mechanisms of Regulatory T Cell Immunosuppression. Frontiers in Immunology, 2011, 2, 60.	4.8	42
69	Exposed Hydrophobic Residues in Human Immunodeficiency Virus Type 1 Vpr Helix-1 Are Important for Cell Cycle Arrest and Cell Death. PLoS ONE, 2011, 6, e24924.	2.5	10
70	Antibodies against insulin measured by electrochemiluminescence predicts insulitis severity and disease onset in non-obese diabetic mice and can distinguish human type 1 diabetes status. Journal of Translational Medicine, 2011, 9, 203.	4.4	22
71	CD4+CD25+Foxp3+ Regulatory T Cells Promote Th17 Cells InÂVitro and Enhance Host Resistance in Mouse Candida albicans Th17 Cell Infection Model. Immunity, 2011, 34, 422-434.	14.3	244
72	Loss of MAGT1 abrogates the Mg2+ flux required for T cell signaling and leads to a novel human primary immunodeficiency. Magnesium Research, 2011, 24, 109-114.	0.5	52

#	Article	IF	Citations
73	The power and the promise of restimulationâ€induced cell death in human immune diseases. Immunological Reviews, 2010, 236, 68-82.	6.0	86
74	Protein Kinase A Phosphorylation Activates Vpr-Induced Cell Cycle Arrest during Human Immunodeficiency Virus Type 1 Infection. Journal of Virology, 2010, 84, 6410-6424.	3.4	35
75	Revised diagnostic criteria and classification for the autoimmune lymphoproliferative syndrome (ALPS): report from the 2009 NIH International Workshop. Blood, 2010, 116, e35-e40.	1.4	405
76	Human genetic approaches to diseases of lymphocyte activation. Immunologic Research, 2009, 43, 8-14.	2.9	1
77	Casein kinase 1Î± governs antigen-receptor-induced NF-ÎºB activation and human lymphoma cell survival. Nature, 2009, 458, 92-96.	27.8	136
78	Restimulation-induced apoptosis of T cells is impaired in patients with X-linked lymphoproliferative disease caused by SAP deficiency. Journal of Clinical Investigation, 2009, 119, 2976-89.	8.2	126
79	14-3-3 theta binding to cell cycle regulatory factors is enhanced by HIV-1 Vpr. Biology Direct, 2008, 3, 17.	4.6	22
80	Critical role for BIM in T cell receptor restimulation-induced death. Biology Direct, 2008, 3, 34.	4.6	41
81	The control of CD4+CD25+Foxp3+ regulatory T cell survival. Biology Direct, 2008, 3, 6.	4.6	74
82	Genetic Defects of Apoptosis and Primary Immunodeficiency. Immunology and Allergy Clinics of North America, 2008, 28, 329-351.	1.9	32
83	Programmed cell death in lymphocytes. , 2008, , 225-234.		0
84	NRAS mutation causes a human autoimmune lymphoproliferative syndrome. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 8953-8958.	7.1	212
85	Vpr Cytopathicity Independent of G 2 /M Cell Cycle Arrest in Human Immunodeficiency Virus Type 1-Infected CD4 + T Cells. Journal of Virology, 2007, 81, 8878-8890.	3.4	51
86	Ribosomal Protein S3: A KH Domain Subunit in NF-ÎºB Complexes that Mediates Selective Gene Regulation. Cell, 2007, 131, 927-939.	28.9	305
87	Essential Role for Caspase-8 in Toll-like Receptors and NFÎºB Signaling. Journal of Biological Chemistry, 2007, 282, 7416-7423.	3.4	137
88	Dominant inhibition of Fas ligand-mediated apoptosis due to a heterozygous mutation associated with autoimmune lymphoproliferative syndrome (ALPS) Type Ib. BMC Medical Genetics, 2007, 8, 41.	2.1	69
89	CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivationâ€“mediated apoptosis of effector CD4+ T cells. Nature Immunology, 2007, 8, 1353-1362.	14.5	1,012
90	GENETIC DISORDERS OF PROGRAMMED CELL DEATH IN THE IMMUNE SYSTEM. Annual Review of Immunology, 2006, 24, 321-352.	21.8	178

#	Article	IF	Citations
91	Autophagic programmed cell death by selective catalase degradation. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 4952-4957.	7.1	619
92	T Helper 2 Cells' Preferred Way to Die. Immunity, 2006, 25, 187-188.	14.3	4
93	Competitive Control of Independent Programs of Tumor Necrosis Factor Receptor-Induced Cell Death by TRADD and RIP1. Molecular and Cellular Biology, 2006, 26, 3505-3513.	2.3	130
94	The Vif and Vpr accessory proteins independently cause HIV-1-induced T cell cytopathicity and cell cycle arrest. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 3369-3374.	7.1	112
95	Amelioration of inflammatory arthritis by targeting the pre-ligand assembly domain of tumor necrosis factor receptors. Nature Medicine, 2005, 11, 1066-1072.	30.7	124
96	Analysis of Human Immunodeficiency Virus Cytopathicity by Using a New Method for Quantitating Viral Dynamics in Cell Culture. Journal of Virology, 2005, 79, 4025-4032.	3.4	18
97	Requirement for Caspase-8 in NF-ÂB Activation by Antigen Receptor. Science, 2005, 307, 1465-1468.	12.6	404
98	Lessons from autoimmune lymphoproliferative syndrome. Drug Discovery Today Disease Mechanisms, 2005, 2, 495-502.	0.8	2
99	Nonapoptotic HIV-Induced T Cell Death. , 2005, , 279-291.		1
100	SPOTS. Journal of Cell Biology, 2004, 167, 735-744.	5.2	137
101	Ectopic T cell receptor expression causes B cell immunodeficiency in transgenic mice. European Journal of Immunology, 2004, 34, 890-898.	2.9	4
102	Regulation of an ATG7-beclin 1 Program of Autophagic Cell Death by Caspase-8. Science, 2004, 304, 1500-1502.	12.6	1,197
103	Molecular Regulation of T Lymphocyte Homeostasis in the Healthy and Diseased Immune System. Immunologic Research, 2003, 27, 387-398.	2.9	40
104	A Role for Tumor Necrosis Factor Receptor-2 and Receptor-interacting Protein in Programmed Necrosis and Antiviral Responses. Journal of Biological Chemistry, 2003, 278, 51613-51621.	3.4	406
105	Death of CD4+ T-Cell Lines Caused by Human Immunodeficiency Virus Type 1 Does Not Depend on Caspases or Apoptosis. Journal of Virology, 2002, 76, 5094-5107.	3.4	63
106	Apoptosis Signaling Pathways. Current Protocols in Cytometry, 2002, 21, Unit 7.18.	3.7	5
107	Cytopathic Killing of Peripheral Blood CD4 + T Lymphocytes by Human Immunodeficiency Virus Type 1 Appears Necrotic rather than Apoptotic and Does Not Require env. Journal of Virology, 2002, 76, 5082-5093.	3.4	83
108	T cell receptor transgenic mice recognizing the immunodominant epitope of the Torpedo californica acetylcholine receptor. European Journal of Immunology, 2002, 32, 2055.	2.9	4

#	Article	IF	Citations
109	Pleiotropic defects in lymphocyte activation caused by caspase-8 mutations lead to human immunodeficiency. Nature, 2002, 419, 395-399.	27.8	648
110	Apoptosis Signaling Pathways. Current Protocols in Immunology, 2001, 44, Unit 11.9C.	3.6	5
111	TcR-Î±/Î²+ CD4âˆ'CD8âˆ' T Cells in Humans with the Autoimmune Lymphoproliferative Syndrome Express a Novel CD45 Isoform That Is Analogous to Murine B220 and Represents a Marker of Altered O-Glycan Biosynthesis. Clinical Immunology, 2001, 100, 314-324.	3.2	85
112	The TNF and TNF Receptor Superfamilies. Cell, 2001, 104, 487-501.	28.9	3,271
113	Immunophenotypic profiles in families with autoimmune lymphoproliferative syndrome. Blood, 2001, 98, 2466-2473.	1.4	129
114	Effective Antigen-Specific Immunotherapy in the Marmoset Model of Multiple Sclerosis. Journal of Immunology, 2001, 166, 2116-2121.	0.8	22
115	Inhibition of Fas-mediated apoptosis by the B cell antigen receptor through c-FLIP. European Journal of Immunology, 2000, 30, 155-163.	2.9	123
116	The multifaceted role of Fas signaling in immune cell homeostasis and autoimmunity. Nature Immunology, 2000, 1, 469-474.	14.5	394
117	TNF-Î±-Induced Secretion of C-C Chemokines Modulates C-C Chemokine Receptor 5 Expression on Peripheral Blood Lymphocytes. Journal of Immunology, 2000, 164, 6180-6187.	0.8	58
118	Signaling by the TNF Receptor Superfamily and T Cell Homeostasis. Immunity, 2000, 13, 419-422.	14.3	187
119	A Domain in TNF Receptors That Mediates Ligand-Independent Receptor Assembly and Signaling. Science, 2000, 288, 2351-2354.	12.6	769
120	Fas Preassociation Required for Apoptosis Signaling and Dominant Inhibition by Pathogenic Mutations. Science, 2000, 288, 2354-2357.	12.6	600
121	Inhibition of Fas-mediated apoptosis by the B cell antigen receptor through c-FLIP. European Journal of Immunology, 2000, 30, 155-163.	2.9	2
122	NF-ÎºB regulates Fasâ€‰/â€‰APO-1â€‰/â€‰CD95- and TCR-mediated apoptosis of T lymphocytes. European Journal of Immunology, 1999, 29, 878-886.	2.9	84
123	MATURE T LYMPHOCYTE APOPTOSISâ€"Immune Regulation in a Dynamic and Unpredictable Antigenic Environment. Annual Review of Immunology, 1999, 17, 221-253.	21.8	881
124	Autoimmune Lymphoproliferative Syndrome with Defective Fas: Genotype Influences Penetrance. American Journal of Human Genetics, 1999, 64, 1002-1014.	6.2	198
125	Inherited Human Caspase 10 Mutations Underlie Defective Lymphocyte and Dendritic Cell Apoptosis in Autoimmune Lymphoproliferative Syndrome Type II. Cell, 1999, 98, 47-58.	28.9	598
126	NMR structure and mutagenesis of the FADD (Mort1) death-effector domain. Nature, 1998, 392, 941-945.	27.8	225

#	Article	IF	Citations
127	Cell death attenuation by `Usurpin', a mammalian DED-caspase homologue that precludes caspase-8 recruitment and activation by the CD-95 (Fas, APO-1) receptor complex. Cell Death and Differentiation, 1998, 5, 271-288.	11.2	293
128	Selective Induction of Apoptosis in Mature T Lymphocytes by Variant T Cell Receptor Ligands. Journal of Experimental Medicine, 1998, 187, 349-355.	8.5	64
129	Membrane Oligomerization and Cleavage Activates the Caspase-8 (FLICE/MACHÎ±1) Death Signal. Journal of Biological Chemistry, 1998, 273, 4345-4349.	3.4	330
130	HIV-1 Directly Kills CD4+ T Cells by a Fas-independent Mechanism. Journal of Experimental Medicine, 1998, 187, 1113-1122.	8.5	184
131	Essential Lymphocyte Function Associated 1 (LFA-1): Intercellular Adhesion Molecule Interactions for T Cellâ€“mediated B Cell Apoptosis by Fas/APO-1/CD95. Journal of Experimental Medicine, 1997, 186, 1171-1176.	8.5	47
132	Introduction: The molecular regulation of lymphocyte apoptosis. Seminars in Immunology, 1997, 9, 1-5.	5.6	72
133	Clinical, Immunologic, and Genetic Features of an Autoimmune Lymphoproliferative Syndrome Associated With Abnormal Lymphocyte Apoptosis. Blood, 1997, 89, 1341-1348.	1.4	358
134	Regulation of thymocyte development from immature progenitors. Current Opinion in Immunology, 1996, 8, 215-224.	5.5	155
135	Mature T Lymphocyte Apoptosis in the Healthy and Diseased Immune System. Advances in Experimental Medicine and Biology, 1996, 406, 229-239.	1.6	5
136	Induction of apoptosis in mature T cells by tumour necrosis factor. Nature, 1995, 377, 348-351.	27.8	1,123
137	Antigen-Induced Programmed T Cell Death as a New Approach to Immune Therapy. Clinical Immunology and Immunopathology, 1995, 75, 13-19.	2.0	41
138	Parameters controlling the programmed death of mature mouse T lymphocytes in high-dose suppression. Cellular Immunology, 1995, 160, 71-78.	3.0	33
139	Dominant interfering fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell, 1995, 81, 935-946.	28.9	1,430
140	Autocrine Feedback Death and the Regulation of Mature T Lymphocyte Antigen Responses. International Reviews of Immunology, 1995, 13, 115-134.	3.3	71
141	Amelioration of Autoimmune Reactions by Antigen-Induced Apoptosis of T Cells. Advances in Experimental Medicine and Biology, 1995, 383, 157-166.	1.6	20
142	Propriocidal apoptosis of mature T lymphocytes occurs at S phase of the cell cycle. European Journal of Immunology, 1993, 23, 1552-1560.	2.9	242
143	Interleukin-2 programs mouse Î±Î² T lymphocytes for apoptosis. Nature, 1991, 353, 858-861.	27.8	1,007
144	The involvement of NF-Î°B in Î²-interferon gene regulation reveals its role as widely inducible mediator of signal transduction. Cell, 1989, 57, 287-294.	28.9	525